Maximizing Local Control And Organ Preservation In Advanced Squamous Cell Head And Neck Cancer (SCHNC) With Hyperfractionated Radiation (HRT) And Concurrent Chemotherapy



Diana Stripp, MD

University of Pennsylvania Cancer
Last Modified: May 13, 2001

Presenter: David J. Adelstein
Affiliation: Cleveland Clinic Foundation, Cleveland, OH.

Background:

  1. 5Fu and cDDP are the best studied and most effective drugs for head and neck cancer.
  2. Both agents are radiosensitizers.
  3. Altered fractionation regimen is more effective than conventional therapy.

Materials and Methods:

  1. 44 patients (pts) with stage III-IV squamous carcinoma of the head and neck were treated on a Cleveland Clinic Foundation clinical trial since January 1996, with HRT (72Gy @ 120cGy b.i.d.) and 2 courses of concurrent chemotherapy using 5-fluorouracil, 1,000 mg/m2/day and cisplatin 20 mg/m2/day; both given as 96 hour continuous intravenous infusions during weeks 1 and 4 of the HRT.
  2. Primary site resection was reserved for residual or recurrent primary site disease after chemoradiotherapy (CRT).
  3. Neck dissection was considered for N2 or greater disease, irrespective of clinical response, and for residual or recurrent neck disease after CRT.

Results:

  1. The median age was 56 (range 42-71) years. All but 3 had stage IV disease
  2. Toxicity included Grade 3-4 mucositis in 98% of pts, dysphagia in 89%, skin reaction in 86% and nausea/vomiting in 7%. Neutropenia occurred in 31 pts (70%).
  3. Forty-two of the 43 evaluable pts achieved a complete primary site response after CRT. The 1 pt with partial response underwent salvage surgery sucessfully.
  4. Twenty-one pts underwent neck dissection; 13 (62%) were pathologically negative.
  5. Distant metastases developed in 8 pts.
  6. With a median follow-up of 30 months, the 2-year overall survival is 81%, and 61% for 3 yr. survival, disease-specific survival 83%, and freedom from recurrence 78%.
  7. At 2 years, local control with salvage surgery, if necessary, is 97%, local control without the need for salvage surgery (i.e. organ preservation) is 90% and distant disease control is 81%.

Authors' Conclusions

  1. This CRT schedule produces considerable but manageable toxicity.
  2. Survival, local control and organ preservation are excellent in this poor prognosis patient cohort.
  3. Distant metastases are now the most common cause of treatment failure.

Clinical/Scientific Implications:

    This agressive combined modality treatment regimen produces good local control and better than expected survival in this group of patients with an extremely poor prognosis. However, toxicity is significant and patients must be selected who can tolerate this agressive management.

ASCO Abstract 893

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

OncoLink I wish u knew...

Dr. Mao discusses why a patient’s culture plays an important role in treatment decisions. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS